The role of glucagon-like peptide-1 receptor agonists in type 1 diabetes has been investigated using exenatide and liraglutide, which have been reported to reduce insulin requirements, promote weight loss, and improve HbA1c levels [43]. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.